Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
06 Mars 2024 - 7:30AM
UK Regulatory
Transgene to Present New Data on TG4050, an Individualized Cancer
Vaccine, at AACR 2024
Poster presentation of new data
from ongoing randomized Phase I trial targeting head and
neck cancers
Strasbourg, France, March 6, 2024,
7:30 a.m. CET – Transgene (Euronext Paris: TNG), a
biotech company that designs and develops virus-based
immunotherapies for the treatment of cancer, will present a poster
on updated data from the ongoing randomized Phase I trial of TG4050
at the American Association for Cancer Research Annual
Meeting (AACR). The AACR will take place in San Diego, California,
USA, from April 5 to 10, 2024.
Poster details
Title: Personalized vaccine
TG4050 induces polyepitopic immune responses against private
neoantigens in resected HPV negative head and neck cancers
- Session title: Late-Breaking Research: Clinical Research 3
- Poster and abstract number: LB401
- Date and Time: Wednesday April 10, 2024, 9:00 a.m. – 12:30 p.m.
PDT
- Location: Poster Section 52, Board number 2
- Authors : A. Lalanne, C. Jamet, JP Delord, C. Ottensmeier,
C. Le Tourneau, A. Tavernaro, G. Lacoste, B. Bastien, M.
Brandely, B. Grellier, E. Quemeneur, Y. Yamashita, O. Kousuke,
N. Yamagata, Y. Tanaka, K. Onoguchi, I. G. Pait, B. Malone,
O. Baker, P. Brattas, M. Gheorghe, R. Stratford, T. Clancy, K.
Bendjama, O. Lantz
The abstract will be available on the AACR
website April 5, 2024, at 3:00 p.m. ET / 9:00 p.m. CET.
TG4050 is an individualized immunotherapy being
developed for solid tumors that is based on Transgene’s
myvac® technology and powered by NEC’s longstanding
artificial intelligence (AI) and machine learning (ML) expertise.
TG4050 is being evaluated in a randomized multicenter Phase I
clinical trial as a single agent in the adjuvant treatment of
HPV-negative head and neck cancers (NCT04183166). Transgene and NEC
plan to continue the development of TG4050 in this indication with
a Phase II extension of the trial expected to start in 2024. TG4050
is being jointly developed by Transgene and NEC.
About Transgene
Transgene (Euronext: TNG) is a biotechnology
company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells.
The Company’s clinical-stage programs consist of a portfolio of
therapeutic vaccines and oncolytic viruses:
TG4050, the first individualized therapeutic vaccine based on the
myvac® platform, TG4001 for the treatment of HPV-positive
cancers, as well as BT-001 and TG6050, two oncolytic viruses based
on the Invir.IO® viral backbone.
With Transgene’s myvac® platform, therapeutic vaccination
enters the field of precision medicine with a novel immunotherapy
that is fully tailored to each individual. The myvac®
approach allows the generation of a virus-based immunotherapy that
encodes patient-specific mutations identified and selected by
Artificial Intelligence capabilities provided by its partner
NEC.
With its proprietary platform Invir.IO®, Transgene is building on
its viral vector engineering expertise to design a new generation
of multifunctional oncolytic viruses.
Additional information about Transgene is available at:
www.transgene.fr
Follow us on social media: X (previously-Twitter): @TransgeneSA –
LinkedIn: @Transgene
Contacts
Transgene:
Lucie Larguier
VP, Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr |
Media: MEDiSTRAVA
Frazer Hall /Sylvie Berrebi
+44 (0)203 928 6900
transgene@medistrava.com |
Disclaimer
This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
- 20240306-Transgene_AACR_curtain_Raiser_TG4050_EN
Transgene (LSE:0OCQ)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Transgene (LSE:0OCQ)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024